» Articles » PMID: 37332758

Collagen Co-localized with Macrovesicular Steatosis Better Differentiates Fibrosis Progression in Non-alcoholic Fatty Liver Disease Mouse Models

Overview
Specialty General Medicine
Date 2023 Jun 19
PMID 37332758
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a global commonly occurring liver disease. However, its exact pathogenesis is not fully understood. The purpose of this study was to quantitatively evaluate the progression of steatosis and fibrosis by examining their distribution, morphology, and co-localization in NAFLD animal models.

Methods: Six mouse NAFLD groups were established: (1) western diet (WD) group; (2) WD with fructose in drinking water (WDF) group; (3) WDF + carbon tetrachloride (CCl4) group, WDF plus intraperitoneal injection of CCl4; (4) high-fat diet (HFD) group, (5) HFD with fructose (HFDF) group; and (6) HFDF + CCl4 group, HFDF plus intraperitoneal injection of CCl4. Liver tissue specimens from NAFLD model mice were collected at different time points. All the tissues were serially sectioned for histological staining and second-harmonic generation (SHG)/two-photon excitation fluorescence imaging (TPEF) imaging. The progression of steatosis and fibrosis was analyzed using SHG/TPEF quantitative parameters with respect to the non-alcoholic steatohepatitis Clinical Research Network scoring system.

Results: qSteatosis showed a good correlation with steatosis grade (: 0.823-0.953,  < 0.05) and demonstrated high performance (area under the curve [AUC]: 0.617-1) in six mouse models. Based on their high correlation with histological scoring, qFibrosis containing four shared parameters (#LongStrPS, #ThinStrPS, #ThinStrPSAgg, and #LongStrPSDis) were selected to create a linear model that could accurately identify differences among fibrosis stages (AUC: 0.725-1). qFibrosis co-localized with macrosteatosis generally correlated better with histological scoring and had a higher AUC in six animal models (AUC: 0.846-1).

Conclusion: Quantitative assessment using SHG/TPEF technology can be used to monitor different types of steatosis and fibrosis progression in NAFLD models. The collagen co-localized with macrosteatosis could better differentiate fibrosis progression and might aid in developing a more reliable and translatable fibrosis evaluation tool for animal models of NAFLD.

Citing Articles

Hepatic Steatosis Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Artificial Intelligence.

Wang X, Song Y, Jin R, Wang Z, Li X, Yang Q Diagnostics (Basel). 2025; 14(24.

PMID: 39767250 PMC: 11675354. DOI: 10.3390/diagnostics14242889.


Diagnostic Value of Hepatic Mast Cell Concentration (MCC) in NAFLD and NASH Severity and Fibrosis Grade.

Panahi M, Rakhshani N, Sarhaddi A, Afzalaghaee M, Rezvani H, Emtiazi N Iran J Pathol. 2024; 19(3):291-299.

PMID: 39687460 PMC: 11646207. DOI: 10.30699/IJP.2024.2016320.3216.


Elongation factor 1A1 inhibition elicits changes in lipid droplet size, the bulk transcriptome, and cell type-associated gene expression in MASLD mouse liver.

Wilson R, Chen Y, Zhang R, Maini S, Andrews T, Wang R Am J Physiol Gastrointest Liver Physiol. 2024; 327(4):G608-G622.

PMID: 39136056 PMC: 11482270. DOI: 10.1152/ajpgi.00276.2023.


The Use of Artificial Intelligence in the Liver Histopathology Field: A Systematic Review.

Grignaffini F, Barbuto F, Troiano M, Piazzo L, Simeoni P, Mangini F Diagnostics (Basel). 2024; 14(4).

PMID: 38396427 PMC: 10887838. DOI: 10.3390/diagnostics14040388.


Leukotriene B4 receptor 1 (BLT1) does not mediate disease progression in a mouse model of liver fibrosis.

Coyne E, Nie Y, Abdurrachim D, Ong C, Zhou Y, Ali A Biochem J. 2023; .

PMID: 38014500 PMC: 10903445. DOI: 10.1042/BCJ20230422.

References
1.
De Rudder M, Bouzin C, Nachit M, Louvegny H, Velde G, Jule Y . Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH. Lab Invest. 2019; 100(1):147-160. DOI: 10.1038/s41374-019-0315-9. View

2.
Huang D, El-Serag H, Loomba R . Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020; 18(4):223-238. PMC: 8016738. DOI: 10.1038/s41575-020-00381-6. View

3.
Ge F, Lobdell 4th H, Zhou S, Hu C, Berk P . Digital analysis of hepatic sections in mice accurately quantitates triglycerides and selected properties of lipid droplets. Exp Biol Med (Maywood). 2010; 235(11):1282-6. PMC: 2965558. DOI: 10.1258/ebm.2010.010095. View

4.
Berardo C, Di Pasqua L, Cagna M, Richelmi P, Vairetti M, Ferrigno A . Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci. 2020; 21(24). PMC: 7766139. DOI: 10.3390/ijms21249646. View

5.
Roth J, Feigh M, Veidal S, Fensholdt L, Rigbolt K, Hansen H . INT-767 improves histopathological features in a diet-induced mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol. 2018; 24(2):195-210. PMC: 5768938. DOI: 10.3748/wjg.v24.i2.195. View